Jaguar Animal Health Declares Special Series O Dividend

Jaguar Animal Health ( (JAGX) ) has provided an announcement.

On February 18, 2026, Jaguar Health’s board declared a special one-time dividend of one-tenth of a share of newly designated Series O Convertible Preferred Stock for each share of common stock outstanding, plus certain eligible warrants, with a record date of March 2, 2026 and expected payment on March 4, 2026. To implement this, Jaguar filed a Delaware certificate designating 1,557,000 Series O shares, which carry no regular dividends or general voting rights, are non-transferable without company consent, rank ahead of common stock for a minimal liquidation preference, and are intended for eventual conversion into common shares subject to ownership caps and possible use of pre-funded warrants.

The Series O Preferred Stock can be issued in fractional increments of one-tenth of a share, converted into common stock at a formula-based ratio linked to the market price, and will automatically convert by December 31, 2026 if the company does not exercise an earlier optional conversion. Jaguar capped any individual holder’s post-conversion ownership at 19.99% of outstanding common stock, may substitute pre-funded warrants to avoid breaching this limit, and confirmed the Series O shares will not be exchange-listed or trade with the common stock, underscoring their role as a structured dividend and capital tool rather than a standalone market security.

The most recent analyst rating on (JAGX) stock is a Hold with a $0.65 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.

Spark’s Take on JAGX Stock

According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.

The score is held down primarily by weak financial performance (large ongoing losses, high leverage, and heavy cash burn) and a bearish technical setup (trading below all major moving averages with negative MACD). Corporate events provide a meaningful positive offset via non-dilutive funding and encouraging clinical progress, but not enough to overcome current financial and trend risks.

To see Spark’s full report on JAGX stock, click here.

More about Jaguar Animal Health

Jaguar Health, Inc., a biopharmaceutical company, focuses on developing and commercializing gastrointestinal products, with its common stock serving as the primary equity security for investors. The company uses preferred stock structures and warrant-linked equity incentives as part of its capital markets strategy and shareholder distributions.

Average Trading Volume: 3,894,202

Technical Sentiment Signal: Sell

Current Market Cap: $2.99M

For a thorough assessment of JAGX stock, go to TipRanks’ Stock Analysis page.